术中地塞米松对婴儿心脏手术主要并发症与死亡率的影响:DECISION随机临床试验
该多中心双盲随机试验纳入394例12个月以下接受体外循环心脏手术的婴儿,比较术中地塞米松1 mg/kg与安慰剂对30天内主要并发症和死亡复合终点的影响。
要点
- 术中地塞米松未显著降低婴儿心脏手术30天主要并发症和死亡风险。
- 主要终点绝对风险降低7.4%,但95%CI跨零(-0.8%至15.3%)。
- 研究可能把握度不足,无法排除临床重要差异。
核心结论
- 在12个月以下接受体外循环心脏手术的婴儿中,术中给予地塞米松与安慰剂相比,未显著减少30天内主要并发症和死亡。
- 研究可能因样本量不足而无法检测出临床重要差异。
研究设计与样本
- 研究者发起的双盲、多中心随机临床试验,涉及中国、巴西和俄罗斯的4个中心。
- 地塞米松组194例,麻醉诱导后静脉给予1 mg/kg地塞米松;对照组200例给予等体积0.9%氯化钠。
主要发现
- 主要复合终点(死亡、非致死性心肌梗死、需ECMO、需心肺复苏、急性肾损伤、延长机械通气或神经系统并发症)在地塞米松组发生74例(38.1%),对照组91例(45.5%)。
- 17项预设次要终点均无统计学显著差异。
- 感染在地塞米松组发生4例(2.0%),对照组3例(1.5%)。
关键数值与推荐
- 主要终点为术后30天内死亡、非致死性心肌梗死、需ECMO、需心肺复苏、急性肾损伤、延长机械通气或神经系统并发症的复合终点。
- 地塞米松剂量为1 mg/kg,麻醉诱导后静脉给药;对照组给予等体积0.9%氯化钠。
- 共17项次要终点,包括主要终点的各组成部分、机械通气时间、正性肌力药物指数、ICU停留时间、ICU再入院和住院时间。
临床怎么用
- 对于12个月以下接受体外循环心脏手术的婴儿,术中常规使用地塞米松以降低主要并发症和死亡风险的证据不支持显著获益。
- 临床决策需结合个体情况,并考虑本研究可能把握度不足的局限性。
局限性
- 研究可能把握度不足,无法检测出临床重要差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Corticosteroids are widely used in pediatric cardiac surgery to blunt systemic inflammatory response and to reduce complications; nevertheless, their clinical efficacy is uncertain. OBJECTIVE: To determine whether intraoperative administration of dexamethasone is more effective than placebo for reducing major complications and mortality during pediatric cardiac surgery. DESIGN, SETTING, AND PARTICIPANTS: The Intraoperative Dexamethasone in Pediatric Cardiac Surgery was an investigator-initiated, double-blind, multicenter randomized trial that involved 4 centers in China, Brazil, and Russia. A total of 394 infants younger than 12 months, undergoing cardiac surgery with cardiopulmonary bypass were enrolled from December 2015 to October 2018, with follow-up completed in November 2018. INTERVENTIONS: The dexamethasone group (n = 194) received 1 mg/kg of dexamethasone; the control group (n = 200) received an equivolume of 0.9% sodium chloride intravenously after anesthesia induction. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of death, nonfatal myocardial infarction, need for extracorporeal membrane oxygenation, need for cardiopulmonary resuscitation, acute kidney injury, prolonged mechanical ventilation, or neurological complications within 30 days after surgery. There were 17 secondary end points, including the individual components of the primary end point, and duration of mechanical ventilation, inotropic index, intensive care unit stay, readmission to intensive care unit, and length of hospitalization. RESULTS: All of the 394 patients randomized (median age, 6 months; 47.2% boys) completed the trial. The primary end point occurred in 74 patients (38.1%) in the dexamethasone group vs 91 patients (45.5%) in the control group (absolute risk reduction, 7.4%; 95% CI, -0.8% to 15.3%; hazard ratio, 0.82; 95% CI, 0.60 to 1.10; P = .20). Of the 17 prespecified secondary end points, none showed a statistically significant difference between groups. Infections occurred in 4 patients (2.0%) in the dexamethasone group vs 3 patients (1.5%) in the control group. CONCLUSIONS AND RELEVANCE: Among infants younger than 12 months undergoing cardiac surgery with cardiopulmonary bypass, intraoperative administration of dexamethasone, compared with placebo, did not significantly reduce major complications and mortality at 30 days. However, the study may have been underpowered to detect a clinically important difference. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02615262.
引用
- Lomivorotov V, Kornilov I, Boboshko V, et al. Effect of Intraoperative Dexamethasone on Major Complications and Mortality Among Infants Undergoing Cardiac Surgery: The DECISION Randomized Clinical Trial. JAMA. 2020. PMID: 32573670. doi:10.1001/jama.2020.8133
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。